Monday, 24 August 2026 01:00 PM
Class Action
NEW YORK CITY, NY / ACCESS Newswire / August 24, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE:EBS). Investors who purchased Emergent securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/emergent-biosolutions-inc-ebs-class_action_lawsuit.
Emergent Investigation Details
On August 5, 2026, Emergent reported results for the quarter ended June 30, 2026. Among other items, Emergent announced, among other things, a $191.3 million non-cash impairment charge on the NARCAN asset group, driving a GAAP net loss of $180.2 million. The Company also cut full-year revenue guidance by approximately 10.8% at the midpoint. Management attributed its results to "increased competitive intensity with implications for our near to medium term outlook and the book value of our NARCAN asset group." Following this news, Emergent's stock price dropped $2.23 per share, or 29.58%, to close at $5.31 on August 6, 2026.
What's Next for Emergent Investors?
If you are aware of any facts relating to this investigation or purchased Emergent securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/emergent-biosolutions-inc-ebs-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Emergent Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Emergent Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz & Grossman, LLC